How does mTOR connect to cancer?
mTORC1 promotes cell growth and proliferation – the same activity that makes it a longevity target makes its hyperactivation a cancer risk. The clearest proof-of-concept is tuberous sclerosis complex, a genetic disorder where losing the TSC1/TSC2 brake leaves mTORC1 switched on without its growth-factor brake and drives tumor growth – and where an mTOR inhibitor (everolimus) is a direct, FDA-approved treatment. mTOR inhibitors are also approved treatments in kidney cancer, hormone-resistant breast cancer, and pancreatic neuroendocrine tumors.
The genetic proof of concept: tuberous sclerosis complex
- FRA2013 H – a phase 3 RCT (n=117) in TSC – the disease where mTOR is left on by a genetic fault that removes its growth-factor brake – showed everolimus shrinks SEGA brain tumors by ≥50% in 35% of patients versus 0% on placebo.
- BIS2013 H – the companion phase 3 RCT (n=118) targeting kidney tumors (angiomyolipomas) in the same disease: everolimus shrank them by ≥50% in 42% of patients.
- GAO2026B H – in a multicenter cohort of 183 TSC-associated renal angiomyolipoma patients, everolimus reduced tumor volume by ≥50% in 44% of patients at 3 months, rising further with continued treatment.
TSC matters because it isolates mTOR as the cause, not just a correlate – the tumors exist specifically because mTORC1 runs without its growth-factor brake (nutrients still gate it), and turning it down pharmacologically shrinks them.
Sporadic cancers where mTOR signaling gets switched on
- BAS2012 H – in hormone-receptor-positive advanced breast cancer, resistance to endocrine therapy is partly driven by mTOR signaling switching on; adding everolimus to endocrine therapy roughly doubled progression-free survival in a phase 3 RCT (n=724).
- HUD2007 H – in poor-prognosis metastatic kidney cancer, temsirolimus (a rapalog) extended median overall survival to 10.9 vs 7.3 months over standard interferon therapy.
- YAO2011 H – in pancreatic neuroendocrine tumors, everolimus more than doubled progression-free survival (11.0 vs 4.6 months) in a phase 3 RCT (n=410), making it a standard treatment for this cancer.
The double-edged-sword problem for longevity research
This is exactly why mTOR inhibition is scientifically interesting for aging, not just cancer: a pathway that drives unwanted growth when overactive is a plausible target for slowing the growth-related decline of aging when partially turned down. But it also means any long-term, population-wide use of mTOR inhibitors for healthy aging needs to reckon with a drug class whose clearest, best-proven human benefit so far is in treating cancers that mTOR hyperactivation helps drive.
Related entities
Thank you. Your answer was counted anonymously.